ARC1779 is the first DNA aptamer that targets the A1 domain of von Willebrand factor (vWF), with indications primarily for thrombotic thrombocytopenic purpura, von Willebrand disease, cerebrovascular embolism, and thrombotic microangiopathy.622 Preliminary evidence suggests that low doses of ARC1779 can be used to correct vWF and/or FVIII deficiencies in patients with hereditary bleeding disorders. Here, VWF is linked to Genetic thrombotic microangiopathy.